A randomized, double-blind, placebo-controlled, six-sequence crossover study evaluating the relative oral abuse potential of NKTR-181 compared to the Schedule II opioid oxycodone in healthy non-dependent recreational drug users experienced in the oral abuse of opioids who can identify drug effects that are relevant to abuse risk assessment

Trial Profile

A randomized, double-blind, placebo-controlled, six-sequence crossover study evaluating the relative oral abuse potential of NKTR-181 compared to the Schedule II opioid oxycodone in healthy non-dependent recreational drug users experienced in the oral abuse of opioids who can identify drug effects that are relevant to abuse risk assessment

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs NKTR 181 (Primary) ; Oxycodone
  • Indications Back pain; Musculoskeletal pain; Pain
  • Focus Pharmacokinetics
  • Acronyms HAP
  • Sponsors Nektar Therapeutics
  • Most Recent Events

    • 07 Nov 2017 According to a Nektar Therapeutics media release, data will be presented at the American College of Neuropsychopharmacology 56th Annual Meeting.
    • 18 Jul 2017 Top line results (n=54) published in a Nektar Therapeutics media release.
    • 18 Jul 2017 Status changed from recruiting to completed according to a Nektar Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top